Leerink Partners Keeps a Hold Rating on Henry Schein (HSIC) With a $69 PT

Henry Schein, Inc. (NASDAQ:HSIC) is one of the 13 Cheap Mid-Cap Stocks to Add to Your PortfolioOn June 16, Leerink Partners analyst Michael Cherny maintained a Hold rating on Henry Schein, Inc. (NASDAQ:HSIC) and set a price target of $69.00.

The company also announced the successful completion of a $250 million strategic investment on May 16, which was extended by funds affiliated with KKR, a leading global investment firm. The closing of the transaction made KKR the holder of around 12% of the company’s common shares.

A close-up of a patient’s mouth, the dental products from the company in view.

Henry Schein, Inc. (NASDAQ:HSIC) reported a 22% growth in GAAP diluted EPS for fiscal Q1 2025, reaching $0.88. Non-GAAP diluted EPS for the quarter underwent a 4.5% rise to $1.15 when compared to the same period last year.

Henry Schein, Inc. (NASDAQ:HSIC) is also advancing its BOLD+1 Strategic Plan, refreshing it for the 2025 to 2027 period. The plan focuses on expanding the company’s corporate brand products and dental and medical specialty businesses, growing its distribution business by improving customer experience and rising operational efficiency, and developing its digital solutions and digital footprint.

Henry Schein, Inc. (NASDAQ:HSIC) provides healthcare services and products to medical, veterinary, and dental office-based practitioners. It operates in the Healthcare Distribution and Technology and Value-Added Services business segments.

While we acknowledge the potential of HSIC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.